Pursuit Of R&D Efficiency Continues As Regulatory Options Expand In 2013 – Tufts CSDD
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Cutting non-core procedures – such as those supporting exploratory endpoints – from study budgets could save the industry $6 billion a year in drug development costs, the Tufts Center for the Study of Drug Development suggests in its 2013 industry outlook report.